Puma Historical Balance Sheet

PBYI Stock

USD 3.07 0.04 1.32%

Trend analysis of Puma Biotechnology balance sheet accounts such as Cash And Short Term Investments of 71.9 M, Common Stock Total Equity of 4.3 K, Common Stock Shares Outstanding of 32.7 M or Liabilities And Stockholders Equity of 165.1 M provides information on Puma Biotechnology's total assets, liabilities, and equity, which is the actual value of Puma Biotechnology to its prevalent stockholders. By breaking down trends over time using Puma Biotechnology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Puma Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Puma Biotechnology is a good buy for the upcoming year.

Puma Biotechnology Inventory

8.17 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

About Puma Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Puma Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Puma Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Puma Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Puma currently owns. An asset can also be divided into two categories, current and non-current.

Puma Biotechnology Balance Sheet Chart

As of now, Puma Biotechnology's Total Current Liabilities is increasing as compared to previous years. The Puma Biotechnology's current Accounts Payable is estimated to increase to about 12.3 M, while Total Assets are projected to decrease to under 165.1 M.

Total Assets Cash And Short Term Investments Common Stock Total Equity Common Stock Shares Outstanding

Add Fundamental

Total Assets

Total assets refers to the total amount of Puma Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Puma Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Puma Biotechnology balance sheet. This account contains Puma Biotechnology investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Puma Biotechnology fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from Puma Biotechnology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's Total Current Liabilities is increasing as compared to previous years. The Puma Biotechnology's current Accounts Payable is estimated to increase to about 12.3 M, while Total Assets are projected to decrease to under 165.1 M.

	2022	2023	2024	2025 (projected)
Total Liabilities	200.5M	177.1M	203.6M	108.6M
Other Stockholder Equity	1.4B	1.4B	1.6B	1.7B

Total Liab Other Stockholder Equity

Puma Biotechnology balance sheet Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Total Current Liabilities	Retained Earnings	Accounts Payable	Other Current Liab	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Inventory
Total Assets		0.15	0.21	0.52	0.49	-0.63	0.51	0.78	0.71	0.89	-0.63	0.69	-0.78	0.53	0.68	0.53	-0.13	0.57	0.67	0.48	0.34	-0.76	0.27	0.62	0.85	-0.03
Total Stockholder Equity	0.15		-0.77	0.37	0.38	-0.27	-0.41	-0.26	-0.59	0.54	-0.27	-0.41	0.39	0.23	-0.54	-0.43	0.93	-0.51	-0.57	0.67	0.57	0.39	0.58	-0.65	-0.28	0.14
Net Debt	0.21	-0.77		-0.52	-0.53	0.05	0.6	0.54	0.72	-0.15	0.05	0.64	-0.6	0.02	0.66	0.44	-0.8	0.59	0.7	-0.22	-0.29	-0.6	-0.06	0.75	0.52	-0.02
Cash	0.52	0.37	-0.52		0.97	-0.44	0.01	0.31	0.16	0.6	-0.44	0.16	-0.27	0.22	0.13	0.2	0.2	0.07	0.12	0.09	0.06	-0.27	-0.25	0.13	0.34	-0.22
Cash And Short Term Investments	0.49	0.38	-0.53	0.97		-0.47	0.02	0.28	0.13	0.58	-0.47	0.14	-0.23	0.2	0.09	0.19	0.21	0.03	0.1	0.08	0.03	-0.23	-0.27	0.09	0.31	-0.25
Common Stock Total Equity	-0.63	-0.27	0.05	-0.44	-0.47		0.1	-0.42	-0.32	-0.63	1.0	-0.39	0.39	-0.39	-0.36	-0.22	0.02	-0.26	-0.32	-0.35	-0.25	0.39	-0.18	-0.26	-0.41	-0.1
Common Stock Shares Outstanding	0.51	-0.41	0.6	0.01	0.02	0.1		0.71	0.72	0.2	0.1	0.67	-0.73	0.12	0.64	0.57	-0.47	0.53	0.78	-0.02	-0.21	-0.72	-0.17	0.62	0.8	-0.11
Other Stockholder Equity	0.78	-0.26	0.54	0.31	0.28	-0.42	0.71		0.83	0.5	-0.42	0.93	-0.96	0.42	0.81	0.64	-0.51	0.7	0.88	0.14	-0.11	-0.98	-0.13	0.78	0.95	-0.15
Total Liab	0.71	-0.59	0.72	0.16	0.13	-0.32	0.72	0.83		0.35	-0.32	0.86	-0.92	0.27	0.94	0.74	-0.77	0.83	0.96	-0.08	-0.13	-0.91	-0.19	0.97	0.9	-0.12
Total Current Assets	0.89	0.54	-0.15	0.6	0.58	-0.63	0.2	0.5	0.35		-0.63	0.37	-0.45	0.55	0.32	0.21	0.28	0.24	0.26	0.68	0.55	-0.44	0.51	0.27	0.55	0.05
Common Stock	-0.63	-0.27	0.05	-0.44	-0.47	1.0	0.1	-0.42	-0.32	-0.63		-0.39	0.39	-0.39	-0.36	-0.22	0.02	-0.26	-0.32	-0.35	-0.25	0.39	-0.18	-0.26	-0.41	-0.1
Total Current Liabilities	0.69	-0.41	0.64	0.16	0.14	-0.39	0.67	0.93	0.86	0.37	-0.39		-0.9	0.25	0.9	0.72	-0.65	0.79	0.9	0.01	-0.24	-0.92	-0.18	0.79	0.87	-0.01
Retained Earnings	-0.78	0.39	-0.6	-0.27	-0.23	0.39	-0.73	-0.96	-0.92	-0.45	0.39	-0.9		-0.43	-0.87	-0.68	0.61	-0.78	-0.94	-0.09	0.07	1.0	0.16	-0.87	-0.97	0.17
Accounts Payable	0.53	0.23	0.02	0.22	0.2	-0.39	0.12	0.42	0.27	0.55	-0.39	0.25	-0.43		0.18	0.06	0.01	0.18	0.23	0.69	0.67	-0.42	0.41	0.26	0.44	0.11
Other Current Liab	0.68	-0.54	0.66	0.13	0.09	-0.36	0.64	0.81	0.94	0.32	-0.36	0.9	-0.87	0.18		0.72	-0.73	0.89	0.93	-0.06	-0.14	-0.87	-0.19	0.88	0.84	-0.01
Other Liab	0.53	-0.43	0.44	0.2	0.19	-0.22	0.57	0.64	0.74	0.21	-0.22	0.72	-0.68	0.06	0.72		-0.58	0.73	0.79	-0.09	-0.19	-0.68	-0.28	0.67	0.68	-0.14
Net Tangible Assets	-0.13	0.93	-0.8	0.2	0.21	0.02	-0.47	-0.51	-0.77	0.28	0.02	-0.65	0.61	0.01	-0.73	-0.58		-0.67	-0.76	0.52	0.48	0.61	0.52	-0.8	-0.51	0.15
Property Plant And Equipment Net	0.57	-0.51	0.59	0.07	0.03	-0.26	0.53	0.7	0.83	0.24	-0.26	0.79	-0.78	0.18	0.89	0.73	-0.67		0.83	-0.05	-0.1	-0.77	-0.18	0.78	0.74	-0.14
Non Current Assets Total	0.67	-0.57	0.7	0.12	0.1	-0.32	0.78	0.88	0.96	0.26	-0.32	0.9	-0.94	0.23	0.93	0.79	-0.76	0.83		-0.09	-0.21	-0.93	-0.27	0.89	0.92	-0.15
Non Currrent Assets Other	0.48	0.67	-0.22	0.09	0.08	-0.35	-0.02	0.14	-0.08	0.68	-0.35	0.01	-0.09	0.69	-0.06	-0.09	0.52	-0.05	-0.09		0.89	-0.08	0.83	-0.15	0.16	0.38
Other Assets	0.34	0.57	-0.29	0.06	0.03	-0.25	-0.21	-0.11	-0.13	0.55	-0.25	-0.24	0.07	0.67	-0.14	-0.19	0.48	-0.1	-0.21	0.89		0.09	0.8	-0.15	-0.01	0.32
Retained Earnings Total Equity	-0.76	0.39	-0.6	-0.27	-0.23	0.39	-0.72	-0.98	-0.91	-0.44	0.39	-0.92	1.0	-0.42	-0.87	-0.68	0.61	-0.77	-0.93	-0.08	0.09		0.17	-0.87	-0.97	0.17
Short Term Investments	0.27	0.58	-0.06	-0.25	-0.27	-0.18	-0.17	-0.13	-0.19	0.51	-0.18	-0.18	0.16	0.41	-0.19	-0.28	0.52	-0.18	-0.27	0.83	0.8	0.17		-0.22	-0.1	0.34
Non Current Liabilities Total	0.62	-0.65	0.75	0.13	0.09	-0.26	0.62	0.78	0.97	0.27	-0.26	0.79	-0.87	0.26	0.88	0.67	-0.8	0.78	0.89	-0.15	-0.15	-0.87	-0.22		0.82	-0.19
Capital Surpluse	0.85	-0.28	0.52	0.34	0.31	-0.41	0.8	0.95	0.9	0.55	-0.41	0.87	-0.97	0.44	0.84	0.68	-0.51	0.74	0.92	0.16	-0.01	-0.97	-0.1	0.82		-0.17
Inventory	-0.03	0.14	-0.02	-0.22	-0.25	-0.1	-0.11	-0.15	-0.12	0.05	-0.1	-0.01	0.17	0.11	-0.01	-0.14	0.15	-0.14	-0.15	0.38	0.32	0.17	0.34	-0.19	-0.17

Click cells to compare fundamentals

Puma Biotechnology Account Relationship Matchups

Puma Biotechnology balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	244.2M	226.6M	222.1M	230.5M	265.1M	165.1M
Total Stockholder Equity	(6M)	(2.4M)	21.6M	53.4M	61.5M	63.0M
Net Debt	35.7M	53.5M	38.1M	26.9M	30.9M	32.5M
Cash	85.3M	63.1M	76.2M	84.6M	97.3M	68.5M
Cash And Short Term Investments	85.3M	63.1M	76.2M	95.9M	110.3M	71.9M
Common Stock Shares Outstanding	39.6M	40.6M	44.9M	47.6M	54.7M	32.7M
Liabilities And Stockholders Equity	244.2M	226.6M	222.1M	230.5M	265.1M	165.1M
Other Stockholder Equity	1.3B	1.4B	1.4B	1.4B	1.6B	1.7B
Total Liab	250.2M	229.0M	200.5M	177.1M	203.6M	108.6M
Total Current Assets	146.1M	140.0M	134.3M	156.2M	179.6M	127.0M
Total Current Liabilities	114.3M	109.6M	77.5M	99.4M	114.3M	120.0M
Retained Earnings	(1.3B)	(1.4B)	(1.4B)	(1.3B)	(1.2B)	(1.2B)
Accounts Payable	12.1M	11.2M	6.4M	6.9M	7.9M	12.3M
Other Current Liab	81.7M	91.3M	66.9M	53.7M	61.8M	45.0M
Other Liab	9M	32.3M	6.4M	12.8M	14.7M	7.6M
Net Tangible Assets	(23.0M)	(80.1M)	(68.6M)	21.6M	19.4M	18.5M
Property Plant And Equipment Net	18.9M	15.8M	12.5M	8.6M	9.9M	8.4M
Non Current Assets Total	98.1M	86.6M	87.8M	74.3M	85.5M	49.8M
Non Currrent Assets Other	5.1M	4.7M	4.7M	4.8M	4.3M	5.1M
Other Assets	5.1M	4.7M	4.7M	1.0	0.9	0.86
Long Term Debt	84.0M	97.1M	98.3M	65.7M	75.5M	54.2M
Retained Earnings Total Equity	(1.3B)	(1.3B)	(1.4B)	(1.4B)	(1.2B)	(1.3B)
Short Term Investments	8.1M	19.0M	4.9M	11.4M	10.2M	9.7M
Non Current Liabilities Total	135.9M	119.4M	123.0M	77.7M	89.4M	68.1M
Capital Surpluse	1.3B	1.3B	1.4B	1.4B	1.6B	952.6M
Inventory	3.5M	7.1M	4.5M	7.1M	6.4M	8.2M
Other Current Assets	23.8M	18.3M	8.3M	4.7M	5.4M	8.4M
Deferred Long Term Liab	5.8M	868K	955K	743K	854.5K	811.7K
Property Plant And Equipment Gross	18.9M	22.6M	1.1M	16.3M	18.8M	19.7M
Accumulated Other Comprehensive Income	62K	0.0	(2K)	(4K)	(4.6K)	(4.8K)
Intangible Assets	74.1M	66.1M	70.6M	60.9M	70.0M	73.5M
Property Plant Equipment	3.3M	2.5M	15.8M	1.1M	1.3M	1.3M
Net Receivables	25.5M	32.5M	40.4M	48.5M	55.8M	58.6M
Short Long Term Debt Total	121.0M	116.6M	114.3M	111.5M	128.2M	123.2M
Long Term Debt Total	151.9M	95.0M	84.0M	97.1M	111.7M	104.8M
Net Invested Capital	92.4M	94.6M	119.9M	153.1M	176.1M	135.2M
Net Working Capital	31.9M	30.4M	56.8M	56.8M	51.1M	49.8M

Currently Active Assets on Macroaxis

F	Ford Motor
GM	General Motors
S	SentinelOne
GOOG	Alphabet Inc Class C
WD	Walker Dunlop

When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:

How To Invest In Puma

Details

Is Puma Stock a good investment?

Details

What is Puma Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

2.417

Earnings Share

0.47

Revenue Per Share

5.045

Quarterly Revenue Growth

0.435

Return On Assets

0.0973

The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Puma Historical Balance Sheet

Puma Biotechnology Inventory

8.17 Million

About Puma Balance Sheet Analysis

Puma Biotechnology Balance Sheet Chart

Total Assets

Cash And Short Term Investments

Common Stock Total Equity

Common Stock Shares Outstanding

Puma Biotechnology balance sheet Correlations

Puma Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Puma Biotechnology balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Retained Earnings Total Equity	+ 1.0	Retained Earnings
Cash And Short Term Investments	+ 0.97	Cash
Non Current Liabilities Total	+ 0.97	Total Liab
Non Current Assets Total	+ 0.96	Total Liab
Capital Surpluse	+ 0.95	Other Stockholder Equity

Retained Earnings Total Equity	- 0.98	Other Stockholder Equity
Capital Surpluse	- 0.97	Retained Earnings Total Equity
Capital Surpluse	- 0.97	Retained Earnings
Retained Earnings	- 0.96	Other Stockholder Equity
Non Current Assets Total	- 0.94	Retained Earnings
Retained Earnings Total Equity	- 0.93	Non Current Assets Total